There are few available data on the incidence and risk factors of thromboembolism in heart failure, and the decision to recommend anticoagulant therapy for these patients is complex. In this Viewpoint, Drs Freudenberger and Halperin discuss the limited existing data on prophylactic approaches to this problem and appeal to physicians to support well-designed, randomized clinical trials of antithrombotic therapy in patients with heart failure.
- Ronald S Freudenberger
- Jonathan L Halperin